logo
Plus   Neg
Share
Email

5 Top Gainers In Healthcare Sector (DOVA, ATOS, ZGNX...)

pharmaup-jun27-lt.jpg

The following are some of today's top gainers in the pharma/biotech sector.

1. Dova Pharmaceuticals Inc. (DOVA)

Gained 27.10% to close Thursday's (June 27) trading at $13.46.

News: The FDA has approved the Company's drug DOPTELET for yet another indication - this time, for the treatment of thrombocytopenia in adults with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment.

DOPTELET was approved in the U.S. for the treatment of severe thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo an invasive procedure on May 21, 2018, and was launched on June 4, 2018. Net product sales from DOPTELET were $7.7 million for the full year ended December 31, 2018.

On June 25 2019, the European Commission approved DOPTELET for the treatment of severe thrombocytopenia in adult patients with CLD who are scheduled to undergo an invasive procedure.

2. China SXT Pharmaceuticals Inc. (SXTC)

China SXT Pharmaceuticals is a pharmaceutical company developing and marketing traditional Chinese medicine pieces, which is a type of Traditional Chinese Medicine that has been processed to be ready for use.

Gained 24.61% to close Thursday's trading at $4.00.

News: No news

Recent event:

On March 28 2019, the Company announced its financial results for the six months ended September 30, 2018.

Net income was $1.00 million, or $0.05 per share, for the six months ended September 30, 2018, compared to $0.79 million, or $0.04 per share, for the same period of the prior fiscal year.

For the six months ended September 30, 2018, total revenues increased to $3.92 million from $3.89 million for the same period of the prior fiscal year.

3. Zogenix Inc. (ZGNX)

Gained 20.91% to close Thursday's trading at $47.65.

News: The Company has solved the two issues with the FDA related to the resubmission of its New Drug Application for FINTEPLA for the treatment of seizures associated with Dravet syndrome.

In April of this year, the FDA had declined to accept for review the FINTEPLA NDA.

In its Refusal to File letter, the FDA stated that certain non-clinical studies were not submitted to allow assessment of the chronic administration of FINTEPLA, and that the application contained an incorrect version of a clinical dataset, which prevented the completion of the review process that is necessary to support the filing of the NDA.

Now that the two issues have been sorted out, the Company intends to resubmit the FINTEPLA NDA in the third quarter of this year.

4. Atossa Genetics Inc. (ATOS)

Gained 15.70% to close Thursday's trading at $2.58.

News: The Company announced that a preliminary analysis from its recently completed phase II study of 20mg daily topical Z Endoxifen showed significant and rapid reduction in mammographic breast density (MBD).

The MBD was reduced by an average of 14.3 percent in the group applying 20mg daily topical Endoxifen, which was statistically significant, according to the Company.

The study enrolled 90 participants who were randomized to one of three different dose groups - placebo; 10mg daily topical Endoxifen; and 20mg daily topical Endoxifen. Participants applied the topical product to the skin of each breast daily for up to six months. Approximately 72 participants eventually developed skin rashes and local irritation and did not complete a full six months of dosing.

Since daily dosing is tied to rashes and local skin irritation in most patients, Atossa will now be evaluating alternative dosing regimens, such as every other day, as well as shorter overall dosing such as fewer than 60 days.

5. TG Therapeutics Inc. (TGTX)

Gained 14.33% to close Thursday's trading at $7.98.

News: No news

Near-term Catalyst:

The Company anticipates submitting New Drug Application for Umbralisib for accelerated approval based on data from the marginal zone lymphoma (MZL) cohort of the UNITY-NHL Phase 2b trial later this year.

The MZL cohort completed enrollment in August 2018, with a total of 69 patients enrolled and receiving at least one dose of Umbralisib. In February of 2019, the Company announced that the MZL cohort met its primary endpoint of overall response rate.

For comments and feedback contact: editorial@rttnews.com

Business News

Follow RTT
>